Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPG11406 in Healthy Adult Participants
NCT06255834Phase 1Completed
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IPG11406 in inflammatory bowel disease (IBD) (9 cohorts), sponsored by Nanjing Immunophage Biotech Co., Ltd. Primary endpoint: Adverse Events up to 17 days. Started Feb 2024; status: completed.
02
Drugs
IPG11406
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06255834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255834.